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Summary 
Equal numbers of CD4 § T ceils recognizing myelin basic protein (MBP) and proteolipid protein 
(PLP) are found in the circulation of normal individuals and multiple  sclerosis  (MS) patients. 
We hypothesized that if myelin-reactive T cells are critical for the pathogenesis of MS, they would 
exist in a different state of activation as compared with myelin-reactive T  cells cloned from the 
blood of normal individuals.  This was investigated in a total of 62 subjects with definitive MS. 
While there were no differences in the frequencies of MBP- and PLP-reactive T ceils after primary 
antigen stimulation, the frequency of MBP or PLP but not tetanus toxoid-reactive T cells generated 
after primary recombinant interleukin (rlL-2) stimulation was significantly higher in MS patients 
as compared with control individuals.  Primary rlL-2-stimulated MBP-reactive T cell lines were 
CD4 + and recognized MBP epitopes 84-102 and 143-168 similar to MBP-reactive T  cell lines 
generated with primary MBP stimulation. In the cerebrospinal fluid (CSF) of MS patients, MBP- 
reactive T cells generated with primary rlL-2 stimulation accounted for 7% of the IL-2-responsive 
cells,  greater  than  10-fold higher  than  paired blood samples,  and these T  cells also  selectively 
recognized MBP peptides 84-102 and 143-168. In striking contrast,  MBP-reactive T cells were 
not detected in CSF obtained from patients with other neurologic diseases. These results provide 
definitive in vitro evidence of an absolute difference in  the  activation  state of myelin-reactive 
T cells in the central nervous system of patients with MS and provide evidence of a pathogenic 
role of autoreactive T  cells in the disease. 
M 
ultiple sclerosis  (MS) 1 is a chronic inflammatory dis- 
ease of the central nervous system (CNS) (1). Although 
the etiology and the pathogenesis of the disease are still un- 
known,  there is increasing  evidence suggesting that  MS is 
a T  cell-mediated  autoimmune  disease  of the CNS white 
matter (reviewed in reference 2). T  cell responses to myelin 
basic protein (MBP) and proteolipid protein (PLP), the two 
most abundant myelin proteins,  are thought to have patho- 
logical importance in MS (reviewed in reference 3). This postu- 
late is supported both by the prominent myelin-specific inflam- 
1 Abbreviations used in  this paper: CNS, central nervous system; CSF, 
cerebrospinal fluid; EAE, experimental autoimmune encephalomyelitis; 
LDA, limiting dilution analysis; MBP, myelin  basic  protein; MS, multiple 
sclerosis; OND, other neurologic diseases; PLP, proteolipid protein; TT, 
tetanus toxoid. 
mation induced by activated but not resting T  cells specific 
for MBP and PLP in experimental autoimmune encephalomy- 
elitis (EAE) and by their pathological role in postinfectious 
encephalomyelitis in humans  (4,  5). 
Recent experiments have indicated that many organ-specific 
autoreactive T cells are not deleted in the thymus and circu- 
late at a low frequency in the periphery (6). These autoreac- 
tive T  cells  may exist without  pathologic consequences as 
they can be isolated from individuals without autoimmune 
disease.  Common to T  cells reactive to other autoantigens, 
autoreactive T cells specific for MBP are present in both pa- 
tients with MS and normal individuals  (7).  They occur at 
a relatively low frequency in peripheral blood mononuclear 
cells,  not  differing  significantly between MS patients  and 
normal individuals (7, 8). The average precursor frequency 
of MBP-specific T  cells is 10-6,  similar  to that  of T  cells 
against exogenous antigens typically found in blood of nonim- 
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munization (9). 
Recent studies in human have demonstrated that T  cell 
responses  to  MBP  are  preferentially directed  at  two  im- 
munodominant  regions,  residues  84-102  and  143-168  of 
human MBP (7,  8,  10,  11). It has also been demonstrated 
in the EAE model that T  cell responses to encephalitogenic 
epitopes can be found in unprimed healthy animals without 
provoking the disease  (12).  The frequency of MBP-specific 
T cells in the peripheral blood of rats with adoptively trans- 
ferred relapsing EAE averages only 1.6  x  10 -5 during the 
first relapse  and 0.5  x  10 -5 during the second relapse  (13). 
Thus, antigen recognition of autoreactive T  cells to the en- 
cephalitogenic epitopes by itself is not sufficient to induce 
the disease. Rather, encephalitogenic  T cells must acquire other 
functional characteristics in order to cross  the blood-brain 
barrier and to mediate autoimmune process in the CNS. The 
major characteristic of encephalitogenic T cells that mediate 
EAE is their activated state since resting T cells are inacces- 
sible to the brain compartment. Thus, we postulate that the 
myelin-reactive T cells in the blood of patients with MS will 
be in a different state of activation as compared with that 
of controls. 
A limiting dilution analysis  (LDA) was performed com- 
paring primary stimulation of T  cells with rlL-2 to either 
MBP, PLP, or tetanus toxoid (TT) to determine the frequency 
of activated T cells recognizing myelin antigens in peripheral 
blood and CSF of patients with MS, subjects with other neu- 
rologic diseases (OND), and normal controls. Additionally, 
MBP-reactive wells were selectively expanded to short-term 
T  cell lines and reactivity to overlapping MBP epitopes ex- 
amined.  An increased frequency of MBP and PLP but not 
TT-reactive T  cells generated by primary rlL-2 stimulation 
was observed in blood of MS patients as compared with con- 
trols. MBP-specific T  cell lines were exclusively CD4 + and 
preferentially recognized epitopes within residues 84-102 and 
143-168 of MBP.  Most importantly, MBP-specific T  cells 
accounted for ,,o7%  IL-2-responsive T  cells  derived from 
cerebrospinal fluid (CSF) of MS patients,  which was >10- 
fold higher than paired blood samples.  In contrast, MBP- 
specific T  cells  were not detectable in CSF samples  of pa- 
tients with OND.  These results provide definitive in vitro 
evidence of an absolute difference in the activation state of 
myelin-reactive T cells in the CNS of patients with MS and 
provides compelling evidence to suggest a pathogenic role 
of autoreactive T  cells  in MS. 
Materials and Methods 
Reagents.  Human MBP was purified from the white matter 
of the human brain by the method previously described by Deibler 
et al. (14). The same MBP preparation was used in all experiments 
described in this study. The MBP peptides were synthesized by 
the Merrifield solid phase method and were purified by high pressure 
liquid chromatography. TT was obtained in purified form from the 
Massachusetts Public Health Laboratory (Boston, MA). rib2 was 
obtained from EuroCetus Inc. (Amsterdam-Zuidoost, The Nether- 
lands). T cell stimulatory activity of this rIL-2 was titrated as com- 
pared with recombinant preparations of  human Ib2 obtained from 
other sources (Boehringer Mannheim Biochemicals, Indianapolis, 
IN; and Genzyme Corp.,  Cambridge, MA). A concentration of 
50 U/ml of rlL-2 (EuroCetus, Inc.) was comparable to 5 U/ml of 
Boehringer Mannheim Biochemicals rlL-2 in activation of resting 
T cells. Lectin-free IL-2 purified by delectinated affanity chroma- 
tography from PHA-stimulated T cell culture supernatant was pur- 
chased from Collaborative Biomedical Products (Bedford, MA). 
Autologous heat-inactivated serum was used for the initial 7 d of 
stimulation, followed  by culture with human serum obtained from 
Sigma Chemical Co. (St. Louis, MO). Media consisted of RPMI 
(Gibco Laboratories, Grand Island, NY) supplemented with 10% 
sera and was otherwise as previously described (7). TT was ob- 
tained from Lederle-Prexis Biologics (Pearl River, NY). 
Patients and CSF Samples.  A group of 62 patients with definite 
MS  (15) characterized clinically predominantly  by a relapsing- 
remitting course were included in this study. Patients had an av- 
erage expanded disability status scale (EDSS) (16, 17) of 3.6 and 
had not received steroids for at least 10 mo before the study. None 
of the patients ever received other immunosuppression. Approxi- 
mately 15-25 ml of CSF was removed by lumbar puncture from 
20 patients with MS and 7 patients with other neurologic diseases 
for diagnostic purposes. Cells used in the experiments were col- 
lected by centrifugation  of CSF at 1,200 rpm for 10 min within 
30 rain after lumbar puncture. Informed consent was obtained from 
each patient,  and the protocol was approved by the Human Sub- 
ject Committee at Brigham and Women's Hospital. Lumbar punc- 
tures were obtained on patients with other neurologic diseases, and 
these are listed in Table 1. 
LDA of Myelin Antigen-specific T Cell Lines  from Peripheral  Blood 
by Primary Stimulation with Myelin Antigens or rib2.  PBMC were 
prepared from heparinized venous blood by Ficoll gradient separa- 
tion. PBMC of each subject were used for two sets of LDA with 
either primary rlL-2 or primary MBP, PLP, or TT stimulation. 
For primary myelin-antigen  stimulation, PBMC were seeded  at lim- 
iting dilution at 2  x  10  s, 105, and 5 x  104 cells per well (60 wells 
for each cell density) in U-bottomed plates (Costar Corp., Cam- 
bridge, MA) and stimulated with either human MBP (40 #g/ml) 
or PLP (50/zg/ml). To stimulate TT-specific  T cells, PBMC were 
plated by limiting dilution  at 105, 5  x  104, and 2.5  x  104 cells 
per well in the presence of 12.5 limit of flocculation/ml of TT. 
For primary IL-2 stimulation, the same cell preparations were plated 
at 2  x  104, 104, and 5  x  103 cells per well (60 wells for each cell 
concentration) in the presence of 50 U/ml of rlL-2. It should be 
noted that these plating cell concentrations were predetermined 
to give optimal clonal response to the antigens. Antigen-stimulated 
wells were cultured without the addition of II.-2. 
On day 8 each well was scored for antigen reactivity by the fol- 
lowing procedure.  105 irradiated (5,000 rad) autologous PBMC 
pulsed with either MBP, PLP, or TT (final  concentration, 2.5 Lf/ml) 
in 200 #1 of media without rlL-2 were added to each well after 
removing the culture supematant. PBMC were pulsed by incubating 
with 100/~g/ml of MBP, PLP, or 12.5 Lf/ml of TT, respectively, 
at 37~  for 4 h and washing away free antigens before irradiation. 
50 U/ml of rlL-2 was added to each well on day 10, and antigen 
reactivity was measured in each well by a split well assay on days 
12-14 (4-6 d after the second stimulation  with antigen-pulsed 
PBMC) to determine which wells contained T cells responding 
specifically to MBP, PLP, or TT. An aliquot of each culture well 
was split into four aliquots ("o104  cells per aliquot) and two wells 
were cultured  in the presence of 10  s autologous  PBMC pulsed 
with the respective  antigen and two control wells received  unpulsed 
PBMC. Cells were cultured for 72 h and then pulsed with 1/zCi 
of [3H]tbymidine per well during the last 16 h of culture and sub- 
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004;  Pharmacia Fine Chemicals, Piscataway, NJ).  [3H]thymidine 
uptake was measured in a beta scintillation counter (betaplate 1205; 
Pharmacia Fine Chemicals). 
Wells were scored positive if the mean Acpm (cpm T cell line 
with APC pulsed with antigen  -  CPM T  cell line APC alone) 
was >1,000 cpm and exceeded the control CPM by at least three 
times.  The number of antigen-reactive wells did not exceed 16% 
of the total wells tested, which implies by the Poisson probability 
that an antigen-specific T cell line derived from a well is most likely 
to originate from a single precursor cell and represents a monoclonal 
response to the antigen. This was confirmed by subsequent cloning 
experiments indicating that specific T  cell clones derived from a 
T cell line were all identical as to their reactivity to a single anti- 
genic peptide and their identical pattern of TCR V gene usage. 
Estimation of the frequency of antigen-specific  T cells was per- 
formed by applying the Poisson Formula (18, 19), in which Fr = 
(u'/r.  9  x  e -u,  where Fr is the probability of obtaining r-specific 
T cells in a well when the average number of precursor cells per 
well is u at a given concentration. The fraction of negative wells 
per total number of wells is given by F0 =  e-~; when u  =  1, Fo = 
0.37.  Therefore, theoretically, when  the average number of re- 
sponding T cells per well is one, 37% of the wells will be scored 
as negative. Extrapolation to this point in limiting dilution gives 
a number of cells, the reciprocal of which represents the frequency 
of the antigen-specific  cells in question. 
LDA of MBP-specific T Cells and IL-2-responsive T Cells in CSF 
and Paired  Blood Samples.  To perform a LDA to determine the fre- 
quencies of IL-2-responsive T cells and MBP-specific T cells in CSF 
compared with paired blood samples, a different protocol was de- 
signed to activate  IL-2 responsive  T  cells by two rounds of II.-2 
stimulation. The protocol allowed effective stimulation of a limited 
number ofT cells obtainable from each lumbar puncture. Specifically, 
CSF  cells  and  paired  PBMC  were  counted  in  duplicate  in  a 
hemocytometer and plated at three different cell concentrations, 
depending on the number of cells obtained from each CSF sample. 
Typically, cells were seeded at 400, 200, and 100 cells per well by 
limiting dilution and were cultured in the presence of 105 irradi- 
ated autologous PBMC and 10% lectin-free IL-2 (,~40 U/ml). This 
concentration of lectin-free 1I,-2 was predetermined to give optimal 
cloning efficiency ofT cells at given concentrations. After 7 d, fresh 
IL-2 with autologous PBMC were added to each well. On day 14, 
all wells were scored microscopically as to whether they were growth 
positive and tested for reactivity to MBP. The same split-well pro- 
tocol as described above was used to determine which wells con- 
tained MBP-reactive T cells using MBP-pulsed and control PBMC. 
The frequencies of IL-2 responsive  and MBP-specific T cells were 
analyzed by the Poisson  statistics  as described above. 
Generation of  MBP-specific T Cell Lines  from Blood/CSF and Peptide 
Analysis.  To examine the peptide reactivity of each MBP-reactive 
well, aliquots of MBP-reactive wells were restimulated with irradi- 
ated PBMC pulsed with MBP in the presence of IL-2, as previously 
reported (7).  104 cells of each MBP-specific T cell line were cul- 
tured with 105 irradiated autologous PBMC or EBV-transformed 
B cells pulsed with the respective  peptides.  Peptide-pulsed  APC 
were prepared by incubating PBMC or B cells with 40 #g/ml of 
peptide or a peptide mix for 4 h and washed two times before ir- 
radiation. Cells were cultured for 72 h and then pulsed with 1/~Ci 
of [3H]thymidine per well during the last 16 h of culture and har- 
vested as described above. 
Flow Cytometry.  Phenotypic expression of the T cell lines was 
analyzed by means of direct immunofluorescence dual staining.  10  s 
T cells were prewashed with ice-cold PBS containing 2% fetal calf 
serum and incubated with monoclonal antibodies directed at CD4, 
CD8, CD45RA (2H4), and CD45RO (UCHL-1) conjugated with 
fluorescein or phycoerythrin (Coulter Immunology, Hialeah, FL; 
and Dakopatts, Copenhagen, Denmark) on ice for 30 min. Cells 
were then washed twice before flow cytometric analysis. Background 
fluorescence  reactivity was  determined  with  phycoerythrin or 
fluorescein-conjugated  mouse Ig. Flow cytometric analysis was per- 
formed by using an Epics C flow cytometer (Coulter Electronics, 
Hialeah, FL) with gates  set to read total cell populations. 
Results 
Frequency Analysis of Resting and Activated MBP- and PLP- 
specific T  Cells.  The clinical characteristics and HLA-DR 
and HLA-DQ haplotypes of MS patients  and control sub- 
jects are shown in Table 1. The frequency of MBP-specific 
T  cells was determined by LDA at three cell concentrations 
predetermined to give maximal and clonal T  cell response 
to MBP (<16% positive wells). PBMC were initially stimu- 
lated under different activation conditions with either MBP 
or IL-2 in 19 patients with MS and 17 normal subjects. Our 
pilot experiments revealed that all cell lines grown in rlL-2 
expressed CD3 phenotype and TCR-a/fl, reflecting the T  cell 
lineage. As shown in Fig. 1, the precursor frequency of T cells 
specific for MBP was  1.1  x  10 -6 in patients with MS  and 
at 0.9  x  10 -6 in normal  subjects.  As previously observed, 
this difference was not statistically significant (Fig.  1, A  vs. 
C; p  >0.5).  In contrast,  the frequency of MBP-reactive T 
cells generated by primary culture with rlL-2 was higher than 
the precursor frequency of MBP-reactive T  cells in 14 of 19 
patients with MS, as compared to 4  of 17 normal subjects. 
The mean frequency of IL-2-generated T ceils specific for MBP 
was 3.2  x  10 -6 in patients with MS and was  1.2  x  10 -6 
in normal donors  (Fig.  1, B  vs.  D; p  <0.02). 
The frequency of IL-2-generated T  cells specific for PLP 
was also examined in a series of patients. As with MBP, the 
precursor frequency of activated PLP-reactive T cells generated 
by primary rlL-2 stimulation  was  higher than  that  gener- 
ated after primary PLP stimulation in patients with MS (1.3 
X  10 -6) as opposed to control subjects (0.3  x  10-6;  Fig. 
1, F-H; p  <0.02).  To examine whether  the increased fre- 
quency of rlL-2-autoreactive T  cells was specific for myelin 
antigens, the precursor frequencies of TT-reactive T cells were 
similarly determined.  As shown in Fig.  1, J  and L,  and in 
contrast to MBP and PLP, the frequency of TT-specific T 
cells generated by primary rlL-2 stimulation represented only 
12-18%  of TT-reactive T  cells in both MS patients  (n  = 
7) and normal subjects (n  =  5) who had been immunized 
with TT >5 yr before the assay. These results indicate that 
the increased frequency of rlL-2-responsive autoreactive T cells 
is  specific for MBP and  PLP myelin antigens. 
Phenotypic Analysis of  MBP-reactive T Cells.  93 MBP-reac- 
tive T cell lines generated by either MBP or IL-2 stimulation 
were  examined  for cell  surface expression of CD4,  CD8, 
CD45tLA, and CD45RO determinants. With one exception, 
all of the MBP-reactive T  cell lines were CD4+CD8 - . These 
CD4+CD8 -  T  cell  lines  could  be  subgrouped  into  two 
subsets according to their CD45RA expression. 36 of 93 MBP- 
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Subject  Age/Sex  EDSS  Diagnosis  Sampling  HLA-DR  HLA-DQ 
MS-1  40/F  2.0  RR 
MS-2  43/M  6.0  RR 
MS-3  42/F  2.5  RR 
MS-4  37/F  2.0  RR 
MS-5  38/F  6.0  CP 
MS-6  42/F  6.0  RR. 
MS-7  31/F  1.5  R.R 
MS-8  30/F  0  RR 
MS-9  42/F  3.5  RR 
MS-10  31/F  0  R.R 
MS-11  38/F  4.0  RI~. 
MS-12  31/F  2.0  RIL 
MS-13  41/F  6.0  RR 
MS-14  45/F  7.5  CP 
MS-15  40/M  1.5  CP 
MS-16  47/M  5.5  RR 
MS-17  46/M  7.5  RR 
MS-18  48/F  2.5  R.R 
MS-19  28/F  2.0  RR 
MS-20  34/F  6.5  CP 
MS-21  42/F  6.0  RR 
MS-22  20/F  3.5  RR 
MS-23  47/F  6.0  RR 
MS-24  42/F  3.5  RR 
MS-25  43/M  6.0  RR 
MS-26  27/M  2.5  RR 
MS-27  37/F  2.0  RR 
MS-28  29/F  6.5  RR 
MS-29  31/F  0  RR 
MS-30  46/F  6.0  RR 
MS-31  29/F  2.0  R.R 
MS-32  38/F  4.0  RR 
MS-33  41/F  6.0  RR 
MS-34  39/M  2.0  RR 
MS-35  31/F  2.0  RR 
MS-36  39/F  2.5  RR 
MS-37  45/F  0  R.R 
MS-38  38/F  1.5  RR 
MS-39  29/F  2.5  RR 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB,CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
PB CSF 
DR2,DR7  DQW1,DQW3 
DR.2 (DRBl-1501)  N.T. 
DR2,DR4  N.T. 
DR2,DRW11,DRW52  DQW1,DQW7 
DR2,DR7,DRW53  DQW1,DQW2 
DR.2 (DRBl-1501)  N.T. 
DR2 (DRB1-1501)  N.T. 
DR2  N.T. 
DR2  (DRB1-1501)  N.T. 
DR2,DR7,DRW53  DWQ1,DQW2, 
DR1,DR2  N.T. 
DR2,DR7,DRW53  DQW1,DQW2 
DR2  (DRB1-1501)  N.T. 
N.T.  N.T. 
DR2 (DRBl-1501)  N.T. 
DR4,DRW8,DRW52,DRW53  DQW4,DQW8 
DR2  DQW1 
DR7,DRW13,DRW52,DRW53  DQW1,DQW2 
DR1,DR2  DQW1 
DR2,DR3,DR52  DQW1,DQW2 
DR2  (DRB1-1501)  N.T. 
DR2,DR6  N.T. 
DR2-  N.T. 
DR2-  N.T. 
DR2  (DRB1-1501)  N.T. 
DR2-  N.T. 
DR2,DRll  N.T. 
DR1,DR3,DRW52  DQW1,DQW2 
DR2,DR7,DRW53  DQW1,DQW2 
DR2,DR3,DRW52  DQW1,DQW2 
DR2-  N.T. 
DR1,DR2  DQW1 
DR2  (DRB1-1501)  N.T. 
DR6,DR7,DRW52,DRW53  DQW1,DQW2 
DR2,DR7,DRW53  DQW1,DQW2 
DR7,DRW6,DRW52,DRW53  DQW2,DQW6 
DR1,DR2  DQW1 
DR2  (DRBl-1501)  N.T. 
DR2,DR4 
continued 
specific T  cell lines examined expressed both CD45RA and 
CD45RO isoforms (Fig. 2 A) while the other 57 T cell lines 
expressed only the CD45RO isoform (Fig.  2 B). As previ- 
ously shown, MBP-specific T cell lines and clones expressed 
either CD45RO or both CD45RA and CD45RO isoforms 
of the leukocyte common antigens (20,  21). The CD45 iso- 
form expression of MBP-specific T cell lines examined in this 
study did not differ between patients with MS and control 
subjects and may be related to the T cell growth cycle at time 
of analysis.  Of 93 short-term MBP-specific T  cell lines,  the 
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Subject  Age/Sex  EDSS  Diagnosis  Sampling  HLA-DR  HLA-DQ 
OND-1  38/F  Neurosarcoidosis  PB,CSF  DR4,DR53,DR7  DQW2,DQW3 
OND-2  27/F  Polyneuropathy  PB,CSF  DR7  DQW1 
OND-3  31/F  Cerebral  palsy  PB,CSF  DR1,DR7  DQW1,DQW2 
OND-4  41/F  Neurosis  PB,CSF  DR2,DR6  DQW1 
OND-5  29/F  Viral meningitis  PB,CSF  DR2,DRW11  DQW1 
OND-6  43/M  Peripheral  neuropathy  PB,CSF  DR4,DRW53  DQW3 
OND-7  28/M  Vertigo  PB,CSF  DR3  DQW1,DQW3 
NS-1  25/M  PB  DR2-  N.T. 
NS-2  21/M  PB  DR6,DR10,DRW52  DQ1,DQ3 
NS-3  32/M  PB  DR1,DR2  DQW1 
NS-4  26/M  PB  DR2-  N.T. 
NS-5  30/F  PB  DR7,DRW53  DQW2,DQW3 
NS-6  30/F  PB  DR7,DRW53  DQ1,DQ2 
NS-7  23/M  PB  DR6,DRW52  DQW1 
NS-8  34/M  PB  DR2  N.T. 
NS-9  25/F  PB  DR2 (DRBl-1501)  N.T. 
NS-10  33/M  PB  DR11 
NS-11  26/F  PB  DR2,DR3,DRW52  DQW1,DQW2 
NS-12  19/F  PB  DR3,DR6,DRW52  DQW1,DQW2 
NS-13  25/F  PB  DR3 
NS-14  31/M  PB  DR2-  N.T. 
NS-15  47/M  PB  DR2-  N.T. 
NS-16  57/F  PB  DR4,DR9,DRW53  DQW8,3,DQW9,3 
NS-17  50/F  PB  DR9,DRW13,6,DRW52,DRW53  DQW7,3,DQW9,3 
N.T., not tested; RR, relapsing-remitting MS; CP, chronic progressive MS; PB, peripheral blood. DR2- is tissue-typed negative for DR2. DR2 
(DRBl-1501) is defined by molecular tissue typing and refers to DR2,Dw2. 
line JA1B2 was CD8 § (98%), CD4-(<1%),  and CD45RA- 
(Fig.  2,  C),  and responded specifically  to peptide  143-168 
(Fig.  3). Attempts to clone this line to further characterize 
its MHC restriction  were unsuccessful. 
Peptide Specificity of MBP-reactive T  Cells from Pe@heral 
Blood.  Reactivity to peptides derived from a sequence of the 
human MBP molecule were determined and data of 29 MBP- 
specific T cell lines, generated after primary stimulation with 
MBP from peripheral  blood, are shown in Fig.  3,  bottom. 
As previously reported, T cell lines preferentially recognized 
the 84-102  and the  143-168 regions  of MBP. 
It was of interest to compare peptide specificity of T  cell 
lines derived by primary rlL-2 stimulation  to lines derived 
by antigen  stimulation.  Specifically,  peptide reactivity was 
examined in 132 MBP-specific T cell lines derived with MBP 
stimulation  and 60 T  cell lines  grown in IL-2  (Fig.  4).  T 
cell lines generated from each patient or normal donor reacted 
predominately to either peptide 84-102 or 143-168 and in 
some subjects both peptides. Moreover, the predominant re- 
activity pattern of T cell lines generated after primary rlL-2 
stimulation correlated with that of MBP-derived T cell lines. 
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Frequency  and Peptide  Specificity  of  MBP-reactive T Cells Gener- 
ated in IL-2 from CSF of Patients with MS and Patients with 
OND  The frequency ofT cell lines after primary IL-2 stim- 
ulation and their reactivity to MBP were examined in the 
CSF of 20 MS patients and 7 patients with OND. The clinical 
data and HLA-DR and HLA-DQ haplotypes of these patients 
are given in Table 1. Fig. 5 illustrates an example of the fre- 
quency analysis plotted according to the Poisson probability 
distribution for a paired blood/CSF sample.  Flow cytometric 
analyses of >3,000 cell lines grown in rIL-2 confirmed that 
>98%  of the lines were CD3 §  and expressed TCR-cr 
An increased frequency of growth-positive wells was ob- 
served after primary IL-2 stimulation that represented exclu- 
sively CD3 + T  cells in the CSF of MS patients as compared 
with paired blood specimen (15.7  ￿  10 -4 vs.  7.8  x  10-4; 
p <0.0001), while there were no differences in the total num- 
bers of inflammatory mononudear cells in the CSF (Table 2). 
LDA of CSF T cells demonstrated a higher frequency of MBP- 
reactive T cells after primary IL-2 stimulation from patients 
with MS as compared with T cells from paired PBMC cultures 
using the same cell concentrations and procedures to generate rid  'o 
x 
O 
I-- 
O 
O 
e~ 
e- 
03 
a., 
c- 
~3 
O 
C 
12 
10- 
8- 
6- 
4- 
2- 
Myelin  Basic Protein 
A  B  I  C  D 
O 
,  / 
/  / 
lo  / 
*  i/ 
/0 
r 
/o 
MS  NS 
Proteoli 
E  F 
0 
P 
t#I  
MS 
lid  Protein 
G  H 
NS 
60 
50- 
40- 
30- 
20~ 
10- 
0 
Tetanus  Toxoid 
!  J  L 
il  , 
MS  NS 
Figure  1.  Frequency analysis of T 
cells reactive  to MBP and PLP in periph- 
eral blood of MS patients and normal 
subjects. 19 patients with MS and 17 
normal subjects were analyzed by LDA 
for the frequency of T cells reactive to 
MBP. Similarly, 16 different patients 
with MS and 10 normal subjects were 
examined for PLP reactivity. The fre- 
quency of T cells reactive to TT was 
tested in seven patients with MS and 
five normal donors. The frequencies of 
antigen-specific T cells were calculated 
according  to the Poisson  statistics.  Paired 
frequencies analyzed in each individual 
subject by antigen stimulation (filled 
circles) and IL-2 stimulation (open circles) 
are connected by a line. The differences 
of  A-B, B-D, E-F, and F-H are statis- 
tically significant (p <0.02). 
the clones  (5.4  x  10 -5 vs.  0.32  x  10-5; p  <0.001).  The 
paired values between CSF and blood are shown in graphic 
form in Fig.  6.  These T  cell lines responded specifically  to 
MBP and expressed exclusively the CD4 phenotype.  Reac- 
tivity of these clones to MBP peptides were investigated. As 
with  peripheral  blood T  cells,  MBP  84-102  and  143-168 
were preferentially recognized by the IL-2-derived CSF T cells 
(Fig.  3). 
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Figure 2.  Flow cytometric analysis  of MBP-specific 
T cell lines derived from patients with MS and con- 
trols. 105 cells of each MBP-specific  T cell line were 
tested in a direct immunostaining  for the CD4, CD8, 
CD45RA, and CD45RO expression. (A) 36 lines that 
stained positively for  CD4,  CD45RA  (2H4),  and 
CD45RO (UCHL-1); and (B) 57 lines that expressed 
CD4 +,  CD45RA-/CD45RO +  phenotypes.  (C) 
Phenotypic  profile of a CD8 + MBP-specific T  cell 
line (JAIB2). g~ 
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Figure  3.  Peptide  specificity of 
MBP-reactive  T  cell  clones  from 
blood vs. CSF. 29 MBPospecific  T 
cell lines  derived  from  peripheral 
blood by MBP or ILo2 stimulation 
and 14 T cell lines derived from CSF 
were tested for reactivity to MBP 
and MBP  peptides.  Reactivity to 
residues 1-83 and 103-143 of MBP 
was assayed by combining the pep- 
tides covering these two regions (7). 
The standard  deviation was <15% 
of the mean CPM. 
The frequency of growth-positive wells and MBP-reactive 
T cells after IL-2 stimulation from the CSF of subjects with 
other neurologic diseases was compared with that of patients 
with MS. In parallel experiments,  the frequency of growth- 
positive wells in the CSF was found to be lower in patients 
with  OND  as  compared  with  the  patients  with  MS  (p 
<0.001), while there were no differences in the frequency of 
IL-2-responsive T cells in the peripheral blood (Table 2 and 
Fig. 6), consistent with observations that the immune system 
is activated in patients with MS. Perhaps of greatest impor- 
tance, 7%  of the T  cells  in  the CSF of patients  with MS 
were MBP reactive and these were not detectable in CSF of 
any of these  patients  with other neurologic diseases. 
Expansion of In Vivo Activated TT-reactive T Cells with rlL-2 
after Immunization.  It was of importance to determine whether 
the precursor frequency of TT-reactive  cells with primary 
MS subjects 
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Figure  4.  Comparison of peptide re- 
activity of MBP-specific T cell lines de- 
rived by MBP with that of T cell lines 
derived by primary  IL-2  stimulation. 
Two panels of MBP-specific T cell lines 
(192 independent lines) subgrouped ac- 
cording to the original stimulus (MBP 
and I1.-2) were tested for their peptide 
reactivity. Data are given as percentage 
of T  cell lines reactive  to a peptide or 
a peptide mix. Actual numbers of pep- 
tide-specific T cell lines are indicated on 
the bar. 
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Figure 5.  Representative frequency analysis of growth-positive  wells 
with primary IL-2 stimulation in paired CSF and peripheral blood.  CSF 
cells and PBMC were counted and plated at limiting dilution with 105 
irradiated autologous  PBMC and 10% lectin-free IL-2 preparation.  The 
frequency (f) of growth-positive wells assessed by an inverted microscope 
was obtained at each cell concentration.  Estimation of the frequency of 
IL-2-responsive T cells was analyzed according to the Poisson statistics. 
rlL-2 stimulation increased after antigen immunization relative 
to the precursor frequency with primary antigen stimulation. 
Thus, we compared the frequency by LDA of antigen-reactive 
T cells after antigen inoculation.  Five normal subjects were 
immunized  subcutaneously with TT and the frequency of 
antigen-reactive T  cells was calculated 5-10 d after primary 
stimulation with either antigen or rlL-2 using the same tech- 
nique used to investigate the frequency of myelin-reactive T 
cells  (Table  3).  In two subjects, we also measured the fre- 
quency of antigen-reactive T cells prior to TT immunization. 
The frequency of TT-reactive T cells with primary rlL-2 stim- 
ulation increased 1 wk after immunization.  However, even 
as early as 5 d after immunization, the frequency of TT-reactive 
T cells generated with primary antigen stimulation was greater 
than  that  obtained with primary rlL-2 cloning.  This is in 
contrast to myelin-reactive T cells in MS patients where the 
frequency of rlL-2-generated clones was higher than that ob- 
tained with  antigen  cloning. 
Discussion 
CD4 § T  cells recognizing  sequestered autoantigens  such 
as MBP and PLP have been demonstrated in the circulation 
of normal individuals as well as in the blood of patients with 
the autoimmune CNS disease MS. A critical question has been 
whether these autoreactive T  cells are pathologic in patients 
with MS but not in normal individuals.  In the EAE model, 
the minimal requirements for autoimmune inflammatory dis- 
ease of the CNS white matter are the presence of either MBP- 
or PLP-reactive CD4 + T  cells that are in an activated as op- 
posed to resting state. This led to the hypothesis that if myelin- 
reactive T  cells are critical for the pathogenesis of MS, they 
would exist in a different state of activation as compared with 
myelin-reactive T cells cloned from the blood of normal in- 
dividuals. We now demonstrate that the frequency of MBP 
and PLP but not TT-reactive T cells generated after primary 
rlL-2 stimulation is significantly higher in the blood and CSF 
of MS patients  as compared with  control  subjects. 
High affinity IL-2 growth factor receptors are transiently 
expressed after T cell stimulation and are associated with T 
cell activation.  As antigen-stimulated  T  cells bearing high 
affinity IL-2R can proliferate in response to IL-2, it has been 
postulated that  IL-2R+-bearing  T  cells represent  lympho- 
cyte populations that have undergone activation and can be 
expanded with IL-2 (22, 23). This was investigated after im- 
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Figure 6.  Frequency analysis of growth-positive 
wells and MBP reactivity of T cells in paired CSF and 
peripheral blood samples after primary IL-2 stimula- 
tion. CSF cells and paired PBMC were plated at lim- 
iting dilution in the presence of 10% lectin-free IL-2 
preparation. On day 14, cultures were scored micro- 
scopically for growth positivity (le~) and tested for 
proliferative response to MBP (right) with autologous 
MBP-pulsed APC in a thymidine-uptake  assay. 
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Frequency of IL-2-responsive T cells  Frequency of MBP-specific T  cells 
Cell counts/ 
Subject  ml CSF  CSF  PBMC  CSF  PBMC 
(A) 
MS-20  12,240  18.0 
MS-21  1,520  10.4 
MS-22  1,210  7.7 
MS-23  1,220  16.6 
MS-24  1,490  17.5 
MS-25  2,040  23.3 
MS-26  3,440  25.0 
MS-27  2,820  7.7 
MS-28  5,040  12.1 
MS-29  4,790  24.3 
MS-30  5,790  23.8 
MS-31  4,630  6.1 
MS-32  2,190  17.8 
MS-33  3,380  25.0 
MS-34  3,820  18.2 
MS-35  4,480  6.2 
MS-36  2,620  12.5 
MS-37  1,240  7.7 
MS-38  4,570  11.1 
MS-39  3,840  23.8 
x lO-4 
(B) 
(13.1-25.7)*  7.4 
(6.1-14.7)  14.7 
(4.3-12.8)  4.7 
(11.5-23.7  13.3 
(13.1-24.2  11.2 
(16.9-32.4)  8.7 
(18.7-33.1)  7.7 
(4.3-11.9)  2.3 
(8.6-17.8)  12.1 
(17.2-32.2)  8.4 
(16.8-32.5)  3.2 
(3.6-11.1)  2.7 
(13.2-24.3)  10.0 
(18.7-33.5)  16.6 
(13.4-24.8)  8.3 
(4.3-11.8)  4.2 
(8.6-18.3)  6.2 
(4.2-13.1)  4.3 
(7.6-17.0)  2.0 
(16.9-32.0)  8.3 
￿ 
(C)  (D) 
(4.1-11.8)  2.6  (1.8-6.6)  0 
(10.2-20.4)  5.5 (4.3-9.2)  0 
(2.9-8.8)  3.8  (2.2-7.2)  0 
(9.9-19.7)  9.1  (6.9-14.8)  0 
(7.8-17.2)  8.3  (5.3-14.5)  0 
(6.4-13.2)  20.0  (14.8-28.0)  0 
(4.2-12.4)  8.4  (6.0-13.5)  1.8 (1.4-3.2) 
(1.7-5.8)  6.7  (4.2-11.8)  1.9 (1.3-4.4) 
(8.8-17.4)  1.7 (1.2-4.3)  0 
(6.4-13.5)  3.4  (2.3-7.4)  0 
(2.2-7.8)  4.9  (2.9-8.6)  0 
(1.8-5.6)  0  0 
(7.8-15.4)  0  0 
(11.5-23.5)  2.4 (1.7-6.9)  0 
(5.8-11.4)  6.6  (5.2-10.8)  0 
(2.4-7.5)  6.4 (5.2-10.7)  0 
(4.6-10.8)  1.4 (1.3-4.5)  0 
(2.7-9.2)  0  0 
(1.4-5.6)  16.5 (11.5-24.1)  2.7 (1.8-5.2) 
(6.0-12.9)  0  0 
Mean  3,620  15.7  7.8  5.4  0.32 
(E)  (F)  (G)  (H) 
OND-1  5,220  10.4 (7.3-16.4)  9.6  (7.3-14.6)  0  0 
OND-2  2,240  7.2  (5.1-10.8)  8.3  (5.8-12.4)  0  0 
OND-3  2,410  4.6  (2.8-9.0)  7.8 (4.2-14.5)  0  0 
OND-4  5,320  4.1  (2.3-8.5)  8.7  (6.4-13.4)  0  0 
OND-5  4,380  4.8  (2.9-9.2)  6.8 (5.2-10.2)  0  0 
OND-6  1,190  3.3  (2.0-7.9)  4.2  (2.4-8.9)  0  0 
OND-7  2,230  2.1  (1.3-5.0)  4.9  (3.8-9.1)  0  0 
Mean  3,260  5.2  6.9  0  0 
Column pair  (A)-(B)  (C)-(D)  (E)-(F)  (A)-(E)  (B)-(F)  (C)-(G) 
p*  0.0001  0.0001  0.165  0.001  0.578  0.0001 
* 95% confidence  limits. 
* Calculated by t test. 
munization with TT followed by a LDA with either pri- 
mary antigen or rlL-2 stimulation.  The frequency of TT- 
reactive T cells was higher after immunization with primary 
rlL-2 or antigen stimulation. The frequency of TT-reactive 
T  cells remained higher after primary antigen as compared 
with rlL-2 stimulation as early as 5 d after immunization. 
This is not  surprising as rlL-2 should stimulate only acti- 
vated T cells that express high affinity IL-2Rs while antigen 
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with Immunization 
Normal  Primary  Pre  Post 
subjects  stimulation  immunization  immunization 
xlO-S 
1  TT  0  1.1 
rlL-2  0  1.1 
2  TT  0  6.2 
rlL-2  0  3.8 
3  TT  ND  21.1 
rIL-2  16.3 
4  TT  ND  2.3 
rlL-2  1.3 
5  TT  ND  3.4 
rlL-2  1.0 
LDA was performed in five subjects 5-10 d after standard immunization 
with TT. Subjects 1 and 2 had not been immunized with TT for >15 yr. 
should result in the stimulation of both resting and activated 
T  cells. 
In normal individuals, the frequency of myelin-reactive T 
cells was either higher or the same with primary antigen stim- 
ulation as compared with rlL-2 stimulation.  In distinct con- 
trast  to the myelin response in normal individuals  and the 
TT response in all subjects, MBP- and PLP-reactive T  cells 
from MS patients after primary rlL-2 stimulation were found 
at a higher frequency compared with primary MBP and PLP 
stimulation. This difference in frequency of MBP- and PLP- 
reactive T  cells  after primary rlL-2  stimulation  in MS pa- 
tients as compared with controls indicates  a distinct  func- 
tional  difference in  the  myelin-reactive  T  cells  in diseased 
subjects. 
What might explain the higher frequency of MBP-reactive 
T cells in MS patients with rIL-2 stimulation as opposed to 
primary antigen stimulation? One possibility is that in vivo 
activated T cells, which are more sensitive to apoptosis after 
TCR signaling and are present at a higher frequency in the 
blood of MS patients, would undergo cytolysis with antigen 
but not IL-2. This hypothesis appears to be unlikely as the 
frequency of TT-reactive T  cells was higher  with primary 
antigen  as compared with  IL-2 stimulation  in  subjects re- 
cently immunized with TT. An alternative hypothesis is that 
MBP-reactive T cells are present at a higher frequency in MS 
patients, but these cells are in a different state of activation 
in the blood and CSF of MS patients such that they proliferate 
to an IL-2R signal but not to a TCIk signal.  While this may 
in part be the definition of anergic T  cells, whether or not 
these myelin-reactive T  cells  identified after primary rIL-2 
stimulation  are indeed anergic will require further  investi- 
gations. 
We have previously described a type of anergy for autoreac- 
tive MBP-T cells in vitro by stimulation with MBP peptides 
in the absence of other antigen-presenting cells, and this anergy 
is due to T cell antigen presentation (24, 25). T cell anergy 
may be induced in vivo, where MBP-specific T cells undergo 
clonal expansion during the disease process and become aner- 
gized when stimulated with breakdown products of MBP, 
which can be reversed  by the addition of rlL-2 (24).  Thus, 
clonally expanded, previously activated T cells from MS pa- 
tients might  be more sensitive to the induction  of anergy, 
and the calculated frequency of MBP-specific T cells measured 
by MBP stimulation may not reflect the actual frequency and 
may be considerably underestimated.  However, whatever mech- 
anisms underlie the differences in frequencies  between MBP- 
and PLP-spedfic T cells stimulated with rlL-2 or myelin an- 
tigens, these results demonstrate clear functional differences 
in activation requirements  between myelin-reactive T  cells 
in the blood of patients with MS as compared with normal 
or OND control subjects. These results are also consistent 
with a recent study that suggested in vivo activation of MBP- 
specific T cells in MS using an hypoxanthine guanine phos- 
phoribosyltransferase  (hprt)-  mutant  assay (26). 
Activated MBP-specific T cell lines derived with primary 
rlL-2  stimulation  preferentially recognized both immuno- 
dominant MBP regions between residues 84-102 and 143-168 
as MBP-stimulated T cells, and similarly expressed the same 
CD4+CD8 -  phenotype.  This  raises  the  question  as  to 
whether a subset of the total precursor pool of autoreactive 
T  cells become activated or whether there is an alternative 
pool of autoreactive T cells that undergo a separate differen- 
tiation process.  To further address this question, experiments 
are underway to define the TCR V-D-J DNA sequences of 
these MBP-specific T cell clones grown in IL-2 as compared 
with  their  MBP-derived counterparts. 
As MS is a disease limited to the CNS, we examined the 
frequency of growth-positive wells and MBP-specific T calls 
after primary  IL-2  stimulation  in  the CSF of MS patients 
as compared with  patients  with  OND.  The  frequency of 
growth-positive  wells  after  primary  IL-2  stimulation  was 
higher  in the CSF of patients  with  MS as compared with 
subjects with OND, while there were no differences in this 
frequency of IL-2-stimulated T cells in the peripheral blood. 
As higher concentrations of IL-2 can stimulate NK cells and 
lymphokine-activated killer (LAK) cells, we determined that 
the wells contained almost exclusively CD3 § T cells. Though 
in the CSF  of MS patients  '~7%  of the T  cells  recognize 
MBP, the antigen  reactivity of the majority of cells is un- 
known. Moreover, it is possible that many CD3 + T cells are 
NK cells. Nevertheless, these observations in total are consis- 
tent with the presence of an activated CNS immune system 
in patients with MS. Perhaps of greatest importance,  a sur- 
prisingly high proportion of T  cells in the CSF of patients 
with MS were MBP reactive and these were not detectable 
in CSF of any of the patients with other neurologic diseases. 
This may provide the most compelling evidence to date of 
a pathogenic  role of autoreactive T  cells in MS. 
The difficulty in detecting MBP-reactive T cells in MS CSF 
was previously explained by a low frequency of MBP-reactive 
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may have been due to cloning with primary antigen stimula- 
tion, as 16 of 20 MS patients exhibited an increased frequency 
of MBP-reactive T cells in CSF as compared with paired blood 
samples with primary IL-2 stimulation.  This observation is 
consistent with other recent studies using different metho- 
dologies that have also suggested that  there is an increased 
number of in vivo activated MBP-specific T cells in the CSF 
of patients  with  MS (27,  28). 
An important  question remains as to how MBP-specific 
T  cells are activated and accumulate in the CNS. It is pos- 
sible that the increased frequency ofT cells responsive to MBP 
in the CSF is a primary event in which myelin-reactive T 
cells are activated in the periphery and acquire the capability 
to  pass  through  the  blood-brain  barrier.  Once  they  have 
trafficked into  the CNS,  these myelin-reactive T  cells may 
be reactivated when  they recognize myelin peptides in the 
context of class II MHC and then recruit other inflamma- 
tory cells such as 3,/di T cells and macrophages into the CNS 
that may be important  in mounting  a substantial  immune 
response (29). The activation of MBP-specific T  cells in the 
periphery may be triggered without MBP, and may involve 
other pathways of T cell activation, such as activation by su- 
perantigens, molecular mimicry, or T-T cell activation (CD2- 
LFA-3/I-CAM-1-LFA-1) (30, 31). Alternatively, the primary 
inflammation  in the CNS may not be mediated by MBP- 
specific T  cells,  and expansion of MBP-specific T  cells may 
be secondary to the release of myelin proteins resulting from 
the destruction  of myelin tissue. 
It has been unknown whether MBP-specific T cells present 
in the peripheral blood and compartmentalized  within the 
CNS originate from the same precursor population(s). That 
is, are MBP-reactive T cells, which are selected and expanded 
in the CNS, different from MBP-reactive T cells selected in 
the periphery? While suppression  in SJL/J mice demonstrated 
selective expansion of MBP-reactive T  cells recognizing  an 
encephalitogenic epitope (MBP 87-99) in the spinal cord not 
recognized by MBP-specific T cells derived from peripheral 
blood (32), in MS patients, identical oligoclonal T cells can 
frequently be found between blood and CSF compartments 
(33, 34). Here, we demonstrate that independent MBP-reactive 
T  cell clones derived from the CSF of MS patients  showed 
a restricted reactivity pattern to the two immunodominant 
regions ofMBP (MBP 84-102 and MBP 143-168) comparable 
to MBP-specific T cells derived from peripheral blood paired 
to the CSF. This observation is consistent with recent inves- 
tigations showing sequence homologies between the TCR 
chain CDR3 region of MBP-reactive T  cells and V~ 5.2 
CDR 3 sequences isolated by PCR from the brain  of pa- 
tients with  MS (35). 
Activated encephalitogenic T cell clones selectively recog- 
nize immunodominant MBP residues. These clones are patho- 
genic in mice and rats and induce EAE (36, 37). We postu- 
late that activated human T  cell clones reactive to PLP and 
immunodominant  MBP epitopes are analogous  to the en- 
cephalitogenic T  cells isolated from animals with EAE and 
thus may represent pathogenic T  cell clones involved in the 
initiation  of MS. 
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